Since LAG3, PDCD1 and TIGIT have long been identified as key immune checkpoints in ccRCC, their blockade has demonstrated satisfactory anti-tumor efficacy in preclinical and clinical studies [34–36]. This evidence concerns the gene PDCD1 and neoplasm.